drugset / Trial / NCT00254982
Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED)
Phase 3
Completed
593 enrolled
Merck Sharp & Dohme LLC
Centocor, Inc. · collabEssex Pharma GmbH · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, multicenter, parallel-group comparison study of the efficacy, safety, and tolerability of infliximab therapy in adult patients suffering from chronic plaque psoriasis (psoriasis vulgaris). Patients will be assigned to GROUP I ("high need") or GROUP II ("low-need") by the investigator according to their previous psoriasis treatment.
Timeline
- Start
- 2005-08
- Primary completion
- 2006-09
- Completion
- 2006-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Infliximab | Monoclonal antibody | 5 mg/kg | — |